MET and cancer: Similar to the findings for all stage IV ADC patients harboring the METex14 mutation, anti-cancer therapy with initial brain metastasis (HR: 5.24, 95% CI: 1.65–16.60; p = 0.005) and strong c-MET IHC staining (HR: 2.06, 95% CI: 1.17–3.62; p = 0.012) consistently predicted poor survival outcomes in these 29 patients.